2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Nom du produit CAS No. Pureté Chemical Structure
  • HY-100196AR
    Pyrroloquinoline quinone disodium salt (Standard) 122628-50-6
    Triazophos (Standard) is the analytical standard of Triazophos. This product is intended for research and analytical applications. Triazophos, a non-systemic insecticide and acaricide that acts as an acetylcholinesterase (AChE) inhibitor, covalently and irreversibly binds to the acetylcholine binding site, thus blocking the hydrolysis of acetylcholine and leading to hyperexcitability; it is effective against a variety of soil insects and mites, including aphids, thrips, midges, beetles, Lepidoptera larvae, cutworms, and spider mites in crops such as ornamentals, cotton, rice, maize, soybeans, oil palms, olives, and coffee.
    Pyrroloquinoline quinone disodium salt (Standard)
  • HY-10019AS1
    Varenicline-d4 hydrochloride 98%
    Varenicline-d4 hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A). Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC50 values of 55 μM and 18 μM, respectively. Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment.
    Varenicline-d4 hydrochloride
  • HY-100441S1
    Treprostinil-13C2,d1 98%
    Treprostinil-13C2,d is the 13C- and deuterium labeled Treprostinil. Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.
    Treprostinil-13C2,d1
  • HY-100441S3
    Treprostinil-d7 98%
    Treprostinil-d7 (UT-15-d7) is a deuterated version of Treprostinil (HY-100441). Treprostinil is a highly potent DP1 and EP2 agonist with EC50s of 0.6 nM and 6.2 nM, respectively.
    Treprostinil-d7
  • HY-104026S1
    L-Kynurenine-d4-1 194546-33-3 99.24%
    L-Kynurenine-d4-1 is deuterium labeled L-Kynurenine. L-Kynurenine is a metabolite of the amino acid L-tryptophan. L-Kynurenine is an aryl hydrocarbon receptor agonist.
    L-Kynurenine-d4-1
  • HY-107855S2
    DL-Mevalonolactone-13C 53771-22-5
    DL-Mevalonolactone-13C ((±)-Mevalonolactone-13C) is the 13C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling.
    DL-Mevalonolactone-13C
  • HY-107855S4
    DL-Mevalonolactone-13C2 287111-36-8
    DL-Mevalonolactone-13C2 ((±)-Mevalonolactone-13C2) is the 13C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling[2][4].
    DL-Mevalonolactone-13C2
  • HY-107867S1
    (Rac)-Clopidogrel hydrogen-d9 sulfate 98%
    (Rac)-Clopidogrel hydrogen-d9 sulfate is the deuterium labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects.
    (Rac)-Clopidogrel hydrogen-d9 sulfate
  • HY-112005GL
    DOPE (GMP Like) 4004-05-1 98%
    DOPE (GMP Like) is the GMP Like class DOPE (HY-112005), and can be used as pharmaceutical excipients. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOPE is a neutral helper lipid for cationic liposome and combines with cationic phospholipids to improve transfection efficiency of naked siRNA.
    DOPE (GMP Like)
  • HY-113066S3
    Guanosine 5'-diphosphate-13C10,15N5 dilithium 98%
    Guanosine 5'-diphosphate-13C10,15N5 (GDP-13C10,15N5) dilithium is 13C and 15N-labeled Guanosine 5'-diphosphate (HY-113066). Guanosine 5'-diphosphate (GDP) is a nucleoside diphosphate that activates adenosine 5'-triphosphate-sensitive K+ channel. Guanosine 5'-diphosphate is a potential iron mobilizer, which prevents the hepcidin-ferroportin interaction and modulates the interleukin-6 (IL-6)/stat-3 pathway. Guanosine 5'-diphosphate can be used in the research of inflammation, such as anemia of inflammation (AI).
    Guanosine 5'-diphosphate-13C10,15N5 dilithium
  • HY-113227S1
    Oxoadipic acid-d2 2755838-46-9
    Oxoadipic acid-d2 is the deuterium labeled Oxoadipic acid (HY-113227). Oxoadipic acid is a key intermediate metabolite in the lysine degradation pathway. The level of Oxoadipic acid is significantly negatively correlated with the abundance of Staphylococcus. That is, the higher the abundance of Staphylococcus-a potential pathogenic bacterium that usually increases in ulcerative colitis-the lower the level of Oxoadipic acid. Oxoadipic acid can be used in the research of ulcerative colitis.
    Oxoadipic acid-d2
  • HY-113252S2
    2-Methoxyestrone-d4 949885-90-9 98.0%
    2-Methoxyestrone-d4 is the deuterium labeled 2-Methoxyestrone. 2-Methoxyestrone is a methoxylated catechol estrogen and metabolite of estrone, with a pKa of 10.81.
    2-Methoxyestrone-d4
  • HY-113335S1
    Trihydroxycholestanoic acid-d5 2936622-49-8 98%
    Trihydroxycholestanoic acid-d5 (Coprocholic acid-d5) is deuterium labeled Trihydroxycholestanoic acid. Trihydroxycholestanoic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Refsum Disease, D Bifunctional Protein Deficiency and Infantile Refsum Disease.
    Trihydroxycholestanoic acid-d5
  • HY-113422S2
    Tetrahydrocorticosterone-d3-1
    Tetrahydrocorticosterone-d3-1 is the deuterium labeled Tetrahydrocorticosterone (HY-113422). Tetrahydrocorticosterone is a type of glucocorticoid with notable anti-inflammatory properties. One of its active forms, 5α-Tetrahydrocorticosterone (HY-113364), acts by binding to the GC receptor and inhibiting inflammatory processes. Tetrahydrocorticosterone is naturally synthesized by the adrenal glands and plays a role in regulating the metabolism of carbohydrates, proteins, and fats.
    Tetrahydrocorticosterone-d3-1
  • HY-114041S1
    Resolvin E1-d4-1 2714040-94-3 98%
    Resolvin E1-d4-1 is the deuterium labeled Resolvin E1. Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production.
    Resolvin E1-d4-1
  • HY-114558S1
    Resmethrin-d6
    Resmethrin-d6 (Benzofuroline-d6) is the deuterium labeled Resmethrin (HY-114558). Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates PPARα activity, with EC50s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.
    Resmethrin-d6
  • HY-116028S1
    15-deoxy-Δ12,14-Prostaglandin D2-d4 2750534-91-7 98%
    15-Deoxy-Δ12,14-Prostaglandin D2-d4 (15-Deoxy-Δ12,14-PGD2-d4) is the deuterium labeled 15-deoxy-Δ12,14-Prostaglandin D2. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is a metabolite of prostaglandin D₂ (PGD₂) (HY-101988), which can undergo further dehydration metabolism to 15-deoxy-Δ12,14-PGJ₂. 15-deoxy-Δ12,14-Prostaglandin D2 is a highly selective agonist for DP2 receptor and PPARγ. 15-deoxy-Δ12,14-Prostaglandin D2 causes morphological changes in eosinophils and migration of type II innate lymphoid cells (ILC2). 15-deoxy-Δ12,14-Prostaglandin D2 has a growth inhibitory effect on prostate cancer cells expressing PPARγ, induces cell cycle arrest and promotes apoptosis. 15-deoxy-Δ12,14-Prostaglandin D2 can be used in related research on asthma and prostate cancer.
    15-deoxy-Δ12,14-Prostaglandin D2-d4
  • HY-117275S1
    Meclofenamic acid-13C6 98%
    Meclofenamic acid-13C6 is the 13C6 labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker.
    Meclofenamic acid-13C6
  • HY-117580S2
    16α-Hydroxyprednisolone-d5
    16α-Hydroxyprednisolone-d5 (OH-PRED-d5) is the deuterium labeled 16α-Hydroxyprednisolone (HY-117580). 16α-Hydroxyprednisolone (OH-PRED) is a stereoselective metabolite of the 22(R) epimer of the glucocorticoid Budesonide (HY-13580). 16α-Hydroxyprednisolone formation is catalyzed by isoenzymes within the cytochrome P450 3A (CYP3A) subfamily. 16α-Hydroxyprednisolone formation can be inhibited by antibodies targeting the CYP3A subfamily.
    16α-Hydroxyprednisolone-d5
  • HY-117985BS
    Evogliptin-d9 tartrate
    Evogliptin-d9 tartrate (DA-1229-d9 tartrate) is the deuterium labeled Evogliptin tartrate (HY-117985B). Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.
    Evogliptin-d9 tartrate
Cat. No. Nom du produit / Synonyms Application Reactivity